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SUMMARY 22 
Background & aims: It has been previously reported that pasta containing wholegrain 23 
sorghum flour exhibits high content of polyphenols and antioxidant capacity and hence might 24 
enhance antioxidant status and reduce markers of oxidative stress in vivo; however no clinical 25 
studies have yet been reported. Therefore, the present study assessed the effect of pasta 26 
containing red or white wholegrain sorghum flour on plasma total polyphenols, antioxidant 27 
capacity and oxidative stress markers in humans. The study was registered with the 28 
Australian New Zealand Clinical Trials Registry (ACTRN: 12612000324819). 29 
Methods: In a randomised crossover design, healthy subjects (n = 20) consumed three test 30 
meals of control pasta (CP), 30% red sorghum pasta (RSP) or 30% white sorghum pasta 31 
(WSP), 1-2 wk apart. The test meals were consumed as breakfast after an overnight fast. 32 
Blood samples were obtained at fasting and 2 h after consumption and analysed for total 33 
polyphenols, antioxidant capacity, superoxide dismutase (SOD) activity, protein carbonyl and 34 
8-isoprostanes.  35 
Results: Compared to baseline, the 2 h post-prandial levels following the RSP meal of plasma 36 
polyphenols, antioxidant capacity and SOD activity were significantly (P ˂ 0.001) higher 37 
while the protein carbonyl level was significantly lower (P = 0.035). Furthermore, net 38 
changes in polyphenols, antioxidant capacity and SOD activity were significantly (P ˂ 0.001) 39 
higher while protein carbonyl were significantly (P = 0.035) lower following consumption of 40 
the RSP meal than the CP meal.  41 
Conclusion: The results demonstrated that pasta containing red wholegrain sorghum flour 42 
enhanced antioxidant status and diminished marker of oxidative stress in healthy subjects.  43 
Key words: Sorghum: Polyphenols: Antioxidant capacity: Oxidative stress: Pasta: 44 
Durum   45 
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1. Introduction 46 
Oxidative stress, an imbalance between the generation of free radical such as reactive 47 
oxygen/nitrogen species and the antioxidant defences, may play a role in the development 48 
and progression of many chronic diseases such as CVD1 and diabetes.2 The antioxidant 49 
defence system consists of endogenous antioxidants glutathione, catalase and superoxide 50 
dismutase (SOD) and exogenous antioxidants obtained by dietary intake, such as 51 
polyphenols.3 Dietary polyphenols have been identified as both powerful chemical 52 
antioxidants and have also been shown to up-regulate the synthesis of endogenous 53 
antioxidants.4  54 
Epidemiological studies have consistently shown an inverse association between the 55 
consumption of polyphenolic-rich foods and the risk of chronic diseases associated with 56 
oxidative stress.5 This is supported by data from cross-sectional studies, which show that 57 
markers of oxidative stress are inversely related to intake of polyphenolic-rich foods.6,7 58 
Furthermore, polyphenolic-rich foods such as apple juice,8 various nuts such as walnut, 59 
almond and pecan,9-12 red wine13 and wholegrain foods such as wheat aleurone-rich bread and 60 
extruded cereals14 have been demonstrated to enhance antioxidant status and improve 61 
markers of oxidative stress in clinical studies.   62 
Consumption of foods containing wholegrain sorghum flour as an ingredient has the potential 63 
to enhance antioxidant status and beneficially modulate markers of oxidative stress. Among 64 
cereal grains, some varieties of sorghum have the highest polyphenolic content.15 These 65 
sorghum polyphenols are known to function as strong antioxidants, at least in vitro.15 In vivo 66 
studies on the oxidative stress related properties of sorghum foods are limited to just one 67 
study conducted on Wistar rats which demonstrated that a diet containing sorghum flour 68 
reduced markers of oxidative stress and inflammation.16   69 
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Studies on the effect of foods containing sorghum flour on antioxidant status and markers of 70 
oxidative stress in humans are lacking and the bioavailability of polyphenols from such foods 71 
has not yet determined. Therefore, the present study aimed to investigate the acute effect of 72 
consumption of pasta containing red or white wholegrain sorghum flour on plasma total 73 
polyphenols, antioxidant capacity and markers of oxidative stress in healthy human subjects. 74 
It was hypothesised that pasta containing the red or white sorghum flour would enhance 75 
plasma polyphenols and antioxidant status (enzymatic and/or non-enzymatic) and would 76 
supress markers of oxidative stress compared to pasta made from durum wheat semolina 77 
only.    78 
 79 
2. Materials and methods 80 
 81 
2.1. Subjects 82 
A total of twenty-two healthy subjects (both male and female) were recruited through posted 83 
flyers, newspaper advertisements and direct personal communication in Melbourne, 84 
Australia. After providing written informed consent, subjects were screened for suitability 85 
using a health questionnaire. Exclusion criteria included: history of cardiovascular disease; 86 
diabetes, asthma, hypertension or gastrointestinal disease; pregnancy; use of medications 87 
(oral contraceptives were allowed); allergy to gluten; smoking; excessive alcohol intake; and 88 
breakfast skipping. The study was conducted according to the guidelines laid down in the 89 
Declaration of Helsinki, and all procedures involving human subjects were approved by the 90 
Deakin University Human Research Ethics Committee. This trial was registered with the 91 
Australian New Zealand Clinical Trials Registry (ACTRN: 12612000324819).   92 
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 93 
2.2. Study design and protocol 94 
A randomised, controlled, cross-over design with at least 1 week wash-out period between 95 
treatments was used. The study was conducted at Deakin University, Burwood campus, 96 
Melbourne, Australia and was initiated on June 20, 2012. Each subject attended three testing 97 
sessions 1-2 wk apart and at each session, consumed one of the three test meals of control 98 
pasta (CP), 30% red sorghum pasta (RSP) or 30% white sorghum pasta (WSP). The test 99 
meals were administered in a random order assigned by computer-generated random numbers 100 
concealed in opaque envelopes that were opened sequentially by the chief investigator. 101 
Subjects were instructed to maintain their usual diet during the study period, but to abstain 102 
from alcohol and vigorous physical activity the day before each study session. Subjects 103 
consumed their evening meal no later than 9:00 pm, after which they fasted (consumption of 104 
500 ml of water was allowed between 9 pm and the next morning). 105 
On the test day, subjects arrived to the laboratory after the 10-12 h overnight fast. Baseline 106 
measurements including weight, height, waist circumference, blood pressure and heart rate 107 
were taken. After 5 min rest in the supine position, a baseline venous blood sample was 108 
drawn into EDTA vacutainers by venepuncture by a qualified phlebotomist. Then, according 109 
to the randomisation schedule, subjects were provided with one of the test meals for 110 
breakfast, which was consumed within 10-12 min. A second venous blood sample was 111 
collected at exactly 2 h after starting the breakfast. This time point was chosen to correspond 112 
to the maximal post-prandial antioxidant capacity and polyphenol concentration in blood 113 
reported in the literature.9,12 The subjects were not allowed to eat or drink anything during the 114 
2 h period, but were allowed to read, watch TV or use their computer.  115 
 116 
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2.3. Test meals 117 
The test meals were three experimental pasta samples (one control and two sorghum- 118 
containing pastas). The control pasta was made from 100% semolina. For the sorghum-119 
containing pastas 30% of the semolina was replaced with either red or white wholegrain 120 
sorghum flour. Tannins may be present in sorghum grain varieties with pigmented testa,   121 
however the red sorghum grain had been previously confirmed as tannin free17 as determined 122 
by the standard bleach test18. The sorghum level used was based on earlier consumer sensory 123 
studies conducted in our laboratory which indicated that a palatable product could be made at 124 
this incorporation level 19. Pasta was prepared as previously reported.20 In terms of nutritional 125 
composition, the sorghum-containing pastas had slightly lower protein and slightly higher fat 126 
and total dietary fibre content than the control.20 All pasta samples were cooked at the 127 
optimal time20 and served warm with 50 g tomato sauce and 200 ml water. The composition 128 
of test meals were calculated using FoodWorks version 7 (Xyris Software, Kenmore Hills, 129 
Qld, Australia) using AusNut database (All Foods, Rev. 14, Food Standards Australia New 130 
Zealand, Canberra, Australia). The database was supplemented with direct analysis of the 131 
experimental foods and manufacturers’ information for foods not found on the database. The 132 
ingredients used in all the test meals and their compositional profiles are given in Table 1. All 133 
test meals contained similar amounts of macronutrients, except dietary fibre that differed 134 
somewhat between the meals. All the test meals were adjusted to an equal weight with 135 
drinking water. 136 
 137 
2.4. Baseline measurements 138 
Height was recorded to the nearest centimetre using a stadiometer (Seca Limited, 139 
Birmingham, UK), and weight was measured with a digital medical scale (model S-YB; 140 
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Wedderburn, Shanghai, China), with the participant wearing light clothing and no shoes. 141 
Height and weight were used to calculate BMI. Waist circumference was measured midway 142 
between the lowest rib margin and iliac crest and recorded to the nearest 0.1 cm. Systolic and 143 
diastolic blood pressures and heart rate were measured in the supine position with an 144 
automatic digital blood pressure monitor (UA-767, A & D Company Limited, Tokyo, Japan). 145 
 146 
2.5. Biochemical analysis 147 
After blood collection, the plasma was separated by centrifugation (1500 x g at 4 oC for 10 148 
min) and aliquots stored at -80 oC until analysis. 149 
 150 
2.5.1. Measurement of plasma total polyphenols 151 
Total phenolic compounds in plasma were determined by a previously published method,13 152 
with some modifications. Briefly, 200 µl of plasma was mixed with 400 µl of 1 mol/L HCl, 153 
vortexed for 1 min, and incubated at 37 oC for 30 min. Then 400 µl of 2 mol/L NaOH in 75% 154 
methanol was added, and the resulting mixture was vortexed for 2 min and incubated at 37 oC 155 
for 30 min. Following this 400 µl of 0.75 mol/L meta-phosphoric acid was added; the 156 
resulting mixture was vortexed for 2 min centrifuged at 1700 x g for 10 min at 4 oC. The 157 
supernatant was collected and kept on ice in the dark, while polyphenols remaining in the 158 
pellet were extracted again by adding 400 µl of a 1:1 (v/v) solution of acetone:water. The 159 
resulting mixture was vortexed for 1 min and centrifuged at 1700 x g for 10 min at 4 oC to 160 
collect the supernatant. The two supernatants were combined and centrifuged at 1700 x g for 161 
5 min at 4 oC. After centrifugation the final supernatant was collected and used for analysis. 162 
For the assay, 500 µl of 0.2 N Folin-Ciocalteu’s phenol reagent and 400 µl of a 2 mol/L 163 
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Na2CO3 solution were added to 100 µl of the final supernatant. After 90 min of incubation in 164 
darkness at room temperature, absorbance at 750 nm was measured using a Synergy 2 165 
microplate reader (BioTek, model S, Winooski, VT, USA). A blank received 100 µl of milli-166 
Q water instead of plasma. Gallic acid (0-500 mg/L), prepared in milli-Q water, was used as 167 
the standard to prepare a calibration curve. The results were expressed as mg of gallic acid 168 
equivalents (GAE) per litre. 169 
 170 
2.5.2. Measurement of total antioxidant capacity 171 
The total antioxidant capacity in plasma samples was determined using a commercially 172 
available assay kit (ImAnOx TAS/TAC kit; Immundiagnostik, Stubenwald-Allee, Bensheim, 173 
Germany), following the manufacturer’s instructions. Briefly, 10 µl of sample or calibrator 174 
was added to appropriate wells of 96-well plate. Then, 100 µl of reagent 1 (reaction buffer A 175 
+ peroxide solution) was added to each well and incubated for 10 min at 37 oC.  Following 176 
this, 100 µl of reagent 2a (reaction buffer A + reaction buffer B + enzyme solution) and 100 177 
µl of reagent 2b (reaction buffer A + reaction buffer B) were added to each well and 178 
incubated for 5 min at room temperature. Finally, stop solution was added to each well and 179 
the plate was read immediately using the Synergy 2 microplate reader (BioTek, model S, 180 
Winooski, VT, USA) at 450 nm. Quantification was performed using the calibrator data and 181 
the results were expressed as µmol of hydrogen peroxide (H2O2) equivalents per litre. 182 
 183 
2.5.3 Measurement of SOD activity 184 
SOD activity was determined by the superoxide dismutase assay kit (Cayman Chemical, Ann 185 
Arbor, MI, USA), according to the manufacturer’s instructions. This assay utilizes xanthine 186 
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oxidase and hypoxanthine to generate superoxide radicals detected by tetrazolium salt. One 187 
unit of SOD is defined as the amount of enzyme required to inhibit the distmutation of the 188 
superoxide radical by 50%. Briefly, 10 µl of plasma or standard was mixed with 200 µl of the 189 
diluted radical detector in a 96-well plate, and the reaction was initiated by adding 20 µl 190 
diluted xanthine oxidase. The plate was covered and incubated with shaking for 20 min. The 191 
absorbance was then read at 450 nm using the Synergy 2 microplate reader (BioTek, model 192 
S, Winooski, VT, USA). Bovine erythrocyte SOD prepared in sample buffer (0-0.25, final 193 
SOD activity U/ml) was used as the standard to prepare the calibration curve. The results 194 
were expressed as units per millilitre (U/ml) of SOD activity.  195 
 196 
2.5.4. Measurement of protein carbonyl 197 
The level of protein carbonyls in plasma were determined using a protein carbonyl assay kit 198 
(Cayman Chemical, Ann Arbor, MI, USA), following the protocol provided by the 199 
manufacturer. Briefly, 200 µl of plasma sample was added into 2 ml plastic tubes, to which 200 
800 µl of 2,4-dinitrophenylhydrazine (DNPH) in 2.5 M HCl was also added. The control tube 201 
received 2.5 M HCl only. Tubes were then incubated for 1 h at room temperature and 202 
vortexed every 15 min. Samples were then precipitated with 1 ml 20% trichloroacetic acid 203 
(TCA) and centrifuged at 10,000 x g for 10 min at 4 oC. The pellets were washed 3 times 204 
with 1 ml ethanol/ethyl acetate mixture (1:1) to remove the DNPH and lipid contaminants. 205 
The final pellet was dissolved in 500 µl of guanidine hydrochloride and insoluble substances 206 
were removed by centrifugation (10,000 x g for 10 min at 4 oC). The supernatant (220 µl) 207 
from the sample and control tubes were transferred to a 96-well plate and the absorbance was 208 
read at 370 nm using the Synergy 2 microplate reader (BioTek, model S, Winooski, VT, 209 
USA). The protein carbonyl content were determined from the difference in absorbance 210 
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between the DNPH-treated and the HCl-treated samples using the molar extinction 211 
coefficient of 22000 M-1cm-1 and were expressed as nmol protein carbonyl per litre. 212 
 213 
2.5.5. Measurement of plasma 8-isoprostanes  214 
The 8-isoprostanes (8-iso-prostaglandin F2α) were analysed in plasma by means of a 215 
competitive immunoassay kit (8-iso-PGF2α EIA kit, Enzo Life Sciences, Farmingdale, NY, 216 
USA) following the manufacturer’s instructions. Prior to analysis plasma samples were 217 
hydrolysed by addition of 50 µl 10 N NaOH to 200 µl plasma samples followed by 218 
incubation at 45°C for 2 hours. Following this, 50 µl 12.1N HCl was added and the samples 219 
were centrifuged for 5 min at 12,000 × g. The supernatant was removed and used for the 220 
assay. Briefly, 50 µl of neutralizing reagent was added to all wells of a goat anti-rabbit IgG 221 
coated microplate, except for the total activity (TA) and blank wells. To the non-specific binding 222 
(NSB) and maximum binding (B0) wells 50 µl sample diluent was added. Next, 50 µl of standard 223 
or sample were added to the appropriate wells. Following this 50 µl conjugate solution was added 224 
to each well except TA and blank wells. Then, 50 µl EIA antibody was added to each well except 225 
TA, NSA and blank wells. The plate was incubated at room temperature with shaking for 2 h. 226 
The wells were then emptied and rinsed 3 times with wash buffer. After the final wash, 200 µl of 227 
p-nitrophenyl phosphate (pNpp) was added to each well and to the TA wells 5 µl of conjugate 228 
solution was also added. The plate was covered and incubated at room temperature for 45 min. 229 
Finally, stop solution was added to all wells and the absorbance was read immediately at 405nm 230 
using the Synergy 2 microplate reader (BioTek, model S, Winooski, VT, USA). 8-iso-231 
prostaglandin F2α (10,0000-160 pg/ml), prepared in sample diluent was used as the standard 232 
to prepar the calibration curve. The results were expressed as pico gram 8-iso-prostaglandin 233 
F2α per millilitre.  234 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
 235 
2.6. Statistical analysis  236 
All results are reported as means ± SEMs unless otherwise indicated. The effect of meal (CP, 237 
RSP and WSP) on plasma total polyphenols and oxidant/antioxidant biomarkers (antioxidant 238 
capacity, SOD activity, protein carbonyl and 8-isoprostane) for intra-group comparison 239 
(baseline vs. 2 h values for each meal) and inter-group comparison (net change = post meal – 240 
pre meal) were evaluated by one-way repeated measures ANOVA with post hoc Bonferroni 241 
test. Pearson’s correlation test between polyphenols and oxidant/antioxidant biomarkers was 242 
performed using the combined data of difference (120 – 0 min postprandial) of all of the 243 
subjects for all the meals. A P ˂ 0.05 was considered to indicate statistical significance. 244 
Statistical analyses were performed by using SPSS statistical software version 21 (SPSS Inc. 245 
Chicago, IL, USA).  246 
 247 
3. Results 248 
 249 
3.1. Baseline characteristics 250 
Of the twenty-two subjects entering the randomisation phase of the study, twenty (six men 251 
and fourteen women) completed the study (Fig. 1); one subject withdrew for personal 252 
reasons; one due to illness unrelated to the study. The characteristics of the study subjects are 253 
shown in Table 2.  254 
 255 
3.2. Plasma total polyphenols 256 
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Plasma polyphenol concentration 2 hours after consumption of the RSP meal was 257 
significantly (P ˂ 0.001) higher than baseline (0 min) (Table 3) and the net change was 258 
significantly (P ˂ 0.001) higher for the RSP meal compared to the CP meal (Fig. 2). No 259 
significant difference in plasma polyphenol was observed after consumption of either WSP 260 
meal or CP meal. 261 
 262 
3.3. Plasma total antioxidant capacity 263 
After the consumption of RSP meal, a significant increase in the total antioxidant capacity of 264 
plasma was found in relation to baseline (0 min) value (P ˂ 0.001, Table 3) and the net 265 
change was significantly (P ˂ 0.001) higher for the RSP meal compared to the CP meal (Fig. 266 
3). There was no significant change in plasma antioxidant capacity after consumption of 267 
either WSP meal or CP meal. 268 
 269 
3.4. Antioxidant enzyme and oxidative stress markers 270 
Markers of antioxidant status and oxidative stress are represented in Table 3. Plasma SOD 271 
activity 2 hours following the RSP meal was significantly (P ˂ 0.001) higher than baseline (0 272 
min) activity and the net change post-prandially (120 min – 0 min) of the RSP meal was 273 
significantly (P = 0.003) higher than that of the CP meal (Fig. 4A). No significant increase in 274 
plasma SOD activity was observed after consumption of either WSP meal or CP meal. 275 
A significant decrease in the protein carbonyl content of plasma was found 120 mins after the 276 
consumption of RSP meal in relation to baseline (0 mins) value (P = 0.035) and the net 277 
change was significantly (P =0.35) lower for the RSP meal compared to the CP meal (Fig 278 
4B). There was no significant decrease in plasma protein carbonyl content after consumption 279 
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of either WSP meal or CP meal (P = 1.00). Plasma 8-isoprostane level did not differ 2 hours 280 
following consumption of any of the test meals compared to their respective baseline (0 mins) 281 
value. In addition, the net changes in 8-isoprostane levels post-prandially of RSP and WSP 282 
meals were also not significantly different compared to the CP meal (Fig. 4C). 283 
 284 
3.5. Associations between post-prandial changes in polyphenol, antioxidant capacity and 285 
markers of oxidative stress 286 
Correlation between post-prandial changes in polyphenols, antioxidants capacity and markers 287 
of oxidative stress is presented in Table 4. Changes in polyphenol level from baseline 288 
correlated positively with changes in antioxidant capacity (r = 0.73, P = 0.001) and SOD 289 
activity (r = 0.47, P = 0.001). Changes in antioxidant capacity correlated positively with 290 
changes in SOD activity (r = 0.44, P = 0.001) and negatively with changes in protein 291 
carbonyl (r = -0.28, P = 0.014).  292 
 293 
4. Discussion 294 
The present study investigated the acute effect of consuming a meal of pasta containing red 295 
or white wholegrain sorghum flour on plasma total polyphenols, antioxidant capacity and 296 
markers of oxidative stress in healthy subjects. The hypothesis was that pasta containing red 297 
or white sorghum would increase plasma total polyphenol, antioxidant capacity and modulate 298 
markers of oxidative stress compared to control pasta. The results showed that RSP but not 299 
WSP increased plasma polyphenol level, antioxidant capacity, endogenous antioxidant 300 
enzyme (SOD) activity and decreased protein carbonyl level compared to CP. 301 
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The increase in plasma polyphenols by the RSP meal may have been a result of its higher 302 
content of polyphenols. Previously it has been reported that pasta containing red wholegrain 303 
sorghum flour at 30% incorporation level contained significantly higher content of 304 
polyphenols compared to control pasta made from durum wheat semolina only.20 The present 305 
results agree with previous acute studies in other polyphenol-rich foods in which increase in 306 
plasma polyphenols levels following consumption was observed.9,10 However, some studies 307 
showed no significant increase in plasma polyphenol levels following consumption of 308 
polyphenol-rich foods.21 These contrasting results may be due to several factors including 309 
poor bioavailability of polyphenols from the intestinal tract,22 large inter-individual variations 310 
in  polyphenols absorption efficiency23 and differences in rate of absorption among different 311 
phenolic compounds.3  Based on the total polyphenolic data presented in Table 1, the 312 
absorption of polyphenols from the RSP meal in the present study is ~5%. It has been 313 
previously shown that the absorption of polyphenols from the intestinal tract is around 2% to 314 
8%20 with most polyphenols undergoing extensive metabolism by intestinal bacteria prior to 315 
absorption and in intestinal tissues during absorption.24  316 
In previous studies an increase in plasma polyphenols level following consumption of 317 
polyphenols rich foods was accompanied by a significant increase in plasma total antioxidant 318 
capacity.9,12 The present study demonstrated an increase in total antioxidant capacity along 319 
with an increase in plasma polyphenolic level only following consumption of the RSP meal, 320 
implying that polyphenols are the major contributors to the increased plasma antioxidant 321 
capacity observed. This is further supported by the significant positive correlation between 322 
polyphenols and antioxidant capacity observed in the present study. Antioxidant capacity 323 
following consumption of the WSP meal did not increase compared to the CP meal, possibly 324 
due to the higher concentration of polyphenols of the red sorghum flour and differences in 325 
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polyphenolic composition, e.g. anthocyanins have been detected in red sorghum only21 and 326 
are strong antioxidants in vitro.25    327 
Antioxidant enzymes such as SOD also contribute to the antioxidant defence system of the 328 
body, providing protection against reactive oxygen species by eliminating superoxide anion 329 
radicals, which have been shown to be involved in damage to cellular membranes.26 In the 330 
present study, the increase in SOD activity observed after the consumption of the RSP meal 331 
may be due to its high levels of polyphenols.  A polyphenol-rich diet has previously been 332 
reported to increase activities of endogenous antioxidant enzymes in animal model and 333 
human studies.11,27 334 
Reactive oxygen species such as superoxide anions and hydroxyl radicals have been shown to 335 
results in protein oxidation in the body.28 Consumption of foods rich in polyphenols have 336 
been shown to decrease protein carbonyl levels, a marker of protein oxidation, in both 337 
diabetic and healthy human subjects.29,30 In line with these findings, the present study 338 
observed a significant reduction in protein carbonyl in plasma following consumption of the 339 
RSP meal compared to the CP meal. The decrease in protein carbonyl may be due to the high 340 
levels of polyphenols and presence of anthocyanins in the RSP meal, leading to increased 341 
radicals scavenging and reduced generation of superoxide anions and hydroxyl radicals.31   342 
The level of 8-isoprostane was measured as a marker of lipid peroxidation in the present 343 
study. The lack of effect of any of the test meals on the level of 8-isoprostane is consistent 344 
with previous acute study in which consumption of dark chocolate as a source of polyphenols 345 
did not affect the level of 8-isoprostane.32 A possible reason for this lack of effect on 346 
isoprostane level may be the short half-life time of isoprostanes in the plasma. It has 347 
previously been reported that urine is a better biological fluid than plasma for determination 348 
of the effects of dietary interventions on isoprostane level, because in urine accumulation of 349 
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the isoprostanes can be measured, whereas isoprostanes in plasma have a short half-life time 350 
and levels vary widely across the day.33  351 
The short duration and use of only one postprandial blood collection are the potential 352 
limitations of the present study and hence the timeline and number of samples should be 353 
increased in future studies. In addition, the activities of other endogenous antioxidant 354 
enzymes such glutathione peroxidase and catalase were not measured. Furthermore, this 355 
study was conducted on healthy subjects only and the results may differ in obese or diabetic 356 
subjects. In addition, studies are required to evaluate the effect of longer term consumption of 357 
polyphenol-rich sorghum foods on biomarkers of chronic disease risk.  358 
In conclusion, the results of the present study show that acute consumption of pasta 359 
containing red wholegrain sorghum flour, but not that containing white wholegrain sorghum 360 
flour, improved antioxidant status by increasing plasma polyphenols, antioxidant capacity 361 
and SOD activity and decreasing a marker of protein oxidation compared to the control 362 
(durum wheat semolina) pasta. These differences in effect between the two sorghum grain 363 
types could be related to the higher polyphenolic content and different profile of polyphenolic 364 
species in red compared to white wholegrain sorghum flour. 365 
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Figure legends: 473 
 474 
Fig. 1. Trial profile showing the number of subjects at each stage of study recruitment and at 475 
completion.  476 
 477 
Fig. 2. Plasma total polyphenols (net change, post meal – pre meal; mean ± SEM) in healthy 478 
subjects (n = 20) after consumption of pasta meals (CP: control pasta; WSP: 30 % white 479 
sorghum pasta; RSP: 30% red sorghum pasta). Bars with different letters are significantly 480 
different. P < 0.05 (one-way repeated ANOVA, Bonferroni adjustment). 481 
 482 
Fig. 3. Plasma antioxidant capacity (net change, post meal – pre meal; mean ± SEM) in 483 
healthy subjects (n = 20) after consumption of pasta meals (CP: control pasta; WSP: 30 % 484 
white sorghum pasta; RSP: 30% red sorghum pasta). Bars with different letters are 485 
significantly different. P < 0.05 (one-way repeated ANOVA, Bonferroni adjustment). 486 
 487 
Fig. 4. (A) SOD activity; (B) protein carbonyl; (C) F2-isoprostane level (net change, post 488 
meal – pre meal; mean ± SEM) in healthy subjects (n = 20) after consumption of pasta meals 489 
(CP: control pasta; WSP: 30 % white sorghum pasta; RSP: 30% red sorghum pasta). Bars 490 
with different letters are significantly different. P < 0.05 (one-way repeated ANOVA, 491 
Bonferroni adjustment). 492 
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Table 1  
Ingredients and energy/nutrient composition of test meals  
 CP WSP RSP 
Ingredients    
Uncooked pasta (g) 67 65 66 
Tomato sauce (g)  50 50 50 
Water (g) 196 200 198 
Total weight (g) 400 400 400 
Energy (kJ) 1119 1112 1113 
Available carbohydrate (g) 50 50 50 
Protein (g) 9.2 8.6 8.5 
Fat (g) 2.6 2.7 2.8 
Total dietary fibre (g) 3.4 3.8 4.2 
Total phenolics (mg GAE)* 31.5 63.0 123.4 
CP: control pasta; WSP: 30% white sorghum pasta; RSP: 30% red sorghum pasta 
*GAE: gallic acid equivalents (Folin Ciocalteu method). 
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Table 2 
 Baseline characteristics of the subjects completing the study (n = 20).* 
 
Variable Value  
Age (y) 23.5 ± 4.3 
Weight (kg)  62.6 ± 10.5 
Height (m) 1.66 ± 0.1 
BMI (kg/m2) 22.5 ± 2.7 
Waist (cm) 76.8 ± 8.4 
Systolic blood pressure (mm Hg) 115.4 ± 7.9 
Diastolic blood pressure (mm Hg) 73.0 ± 6.2 
Heart rate (bpm) 80.7 ± 12.4 
* Values are means ± SD 
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Table 3  
Plasma total polyphenols, total antioxidant capacity, SOD activity, protein carbonyl and 8-
isoprostane levels in healthy subjects before and after consuming the test meals 
 
Test 
meal 
Time 
(min) 
Total 
polyphenols  
(mg GAE/L) 
Total 
antioxidant 
capacity  
(µmol/l) 
SOD activity 
(U/ml) 
Protein 
carbonyl 
(nmol/l)  
8-isoprostane 
(pg/ml) 
 
CP 0 215.16 ± 3.97 307.86 ± 2.49 8.82 ± 0.52 37.92 ± 2.41 51.22 ± 0.36 
 120 212.26 ± 3.85 312.83 ± 3.32 8.88 ± 0.25 41.05 ± 3.90 51.56 ± 0.58 
WSP 0 215.19 ± 2.99 305.44 ± 4.35 9.22 ± 0.40 34.91 ± 3.02 51.47 ± 0.46 
 120 224.41 ± 3.02 318.09 ± 3.56 10.98 ± 0.70 30.66 ± 1.73 51.87 ± 0.52 
RSP 0 216.90 ± 2.62 297.08 ± 5.13 10.16 ± 0.51 38.01 ± 2.93 51.96 ± 0.37 
 120 269.40 ± 2.33* 375.44 ± 2.11* 13.66 ± 0.67* 28.23 ± 1.63* 50.59 ± 0.51 
CP: control pasta; WSP: 30% white sorghum pasta; RSP: 30% red sorghum pasta.  All values 
are means ± SEMs (n =20).  *Significantly different from 0 mins, P < 0.05 (one-way repeated 
ANOVA, Bonferroni adjustment). 
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Table 4  
Correlation between plasma total polyphenols (TP), total antioxidant capacity (TAC) and 
oxidative stress biomarkers 
 SOD activity 8-isoprostane Protein carbonyl Antioxidant capacity 
Total polyphenols 0.47 (p = 0.001)** -0.14 (p = 0.13) -0.20 (p = 0.056) 0.73 (p = 0.001)** 
Antioxidant capacity 0.44 (p = 0.001)** -0.19 (p = 0.066) -0.28 (p = 0.014)*  
Protein carbonyl -0.05 (p = 0.347) 0.06 (p = 0.336)   
8-isoprostane -0.07 (p = 0.286)    
Values are correlation coefficients. *Correlation coefficients are significant (p ≤ 0.05). 
**Correlation coefficients are significant (p ≤ 0.01).  
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CONSORT 2010 checklist of information to include 
when reporting a randomised trial* 
 
 
Section/Topic Item 
No 
Checklist item Reported on page 
No 
Title and 
abstract 
      
 1a Identification as a randomised trial in the title  1 
 1b Structured summary of trial design, methods, 
results, and conclusions (for specific guidance see 
CONSORT for abstracts) 
 1 & 2 
Introduction    
Background 
and objectives 
2a Scientific background and explanation of rationale  3 
 2b Specific objectives or hypotheses  4 
Methods    
Trial design 3a Description of trial design (such as parallel, 
factorial) including allocation ratio 
 5 
 3b Important changes to methods after trial 
commencement (such as eligibility criteria), with 
reasons 
 N/A 
Participants 4a Eligibility criteria for participants  4 
 4b Settings and locations where the data were 
collected 
 5 
Interventions 5 The interventions for each group with sufficient 
details to allow replication, including how and 
when they were actually administered 
 5,6 
Outcomes 6a Completely defined pre-specified primary and 
secondary outcome measures, including how and 
when they were assessed 
 6,7,8,9,10 
 6b Any changes to trial outcomes after the trial 
commenced, with reasons 
 N/A 
Sample size 7a How sample size was determined  4 
 7b When applicable, explanation of any interim 
analyses and stopping guidelines 
 N/A 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation 
sequence 
 5 
 8b Type of randomisation; details of any restriction 
(such as blocking and block size) 
 5 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random 
allocation sequence (such as sequentially 
numbered containers), describing any steps taken 
to conceal the sequence until interventions were 
assigned 
 5 
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
Implementation 
10 Who generated the random allocation sequence, 
who enrolled participants, and who assigned 
participants to interventions 
 5 
Blinding 11a If done, who was blinded after assignment to 
interventions (for example, participants, care 
providers, those assessing outcomes) and how 
 N/A 
 11b If relevant, description of the similarity of 
interventions 
 N/A 
Statistical 
methods 
12a Statistical methods used to compare groups for 
primary and secondary outcomes 
 10 
 12b Methods for additional analyses, such as 
subgroup analyses and adjusted analyses 
 N/A 
Results    
Participant flow 
(a diagram is 
strongly 
recommended) 
13a For each group, the numbers of participants who 
were randomly assigned, received intended 
treatment, and were analysed for the primary 
outcome 
 27 
 13b For each group, losses and exclusions after 
randomisation, together with reasons 
 27 
Recruitment 14a Dates defining the periods of recruitment and 
follow-up 
 5 
 14b Why the trial ended or was stopped  N/A 
Baseline data 15 A table showing baseline demographic and 
clinical characteristics for each group 
 25 
Numbers 
analysed 
16 For each group, number of participants 
(denominator) included in each analysis and 
whether the analysis was by original assigned 
groups 
 11 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results 
for each group, and the estimated effect size and 
its precision (such as 95% confidence interval) 
 11,12 
 17b For binary outcomes, presentation of both 
absolute and relative effect sizes is recommended 
 N/A 
Ancillary 
analyses 
18 Results of any other analyses performed, 
including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from 
exploratory 
 13 
Harms 19 All important harms or unintended effects in each 
group (for specific guidance see CONSORT for 
harms) 
 N/A 
Discussion    
Limitations 20 Trial limitations, addressing sources of potential 
bias, imprecision, and, if relevant, multiplicity of 
analyses 
 15 
Generalisability 21 Generalisability (external validity, applicability) of 
the trial findings 
 13,14,15 
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Interpretation 22 Interpretation consistent with results, balancing 
benefits and harms, and considering other 
relevant evidence 
 16 
Other 
information 
  
 
Registration 23 Registration number and name of trial registry  4 
Protocol 24 Where the full trial protocol can be accessed, if 
available 
 5 
Funding 25 Sources of funding and other support (such as 
supply of drugs), role of funders 
 16 
 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation 
and Elaboration for important clarifications on all the items. If relevant, we also recommend reading 
CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-
pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are 
forthcoming: for those and for up to date references relevant to this checklist, see www.consort-
statement.org. 
 
 
 
